BRÈVE

sur Bausch Health Companies Inc. (NASDAQ:BHC)

Bausch Health Appoints New Chief Medical Officer and Head of R&D

Graphique de l'évolution du cours de l'action Bausch Health Companies Inc. (EBR:BHC).

Bausch Health Companies Inc. has announced the appointment of Jonathan Sadeh, M.D., M.Sc as Executive Vice President, Chief Medical Officer, and Head of R&D. The company emphasizes this as a strategic move to bolster its focus on innovation and excellence.

Jonathan Sadeh brings over 20 years of experience in clinical research and drug development, with a history of multiple drug approvals at Bristol-Meyers Squibb. His past roles include leadership in dermatology and gastroenterology, as well as global programs head for various therapeutic areas. His academic credentials include a medical degree from Mount Sinai School of Medicine and a master's degree from Harvard Medical School.

In his role at Bausch Health, Jonathan will oversee the R&D process and align it with the company’s goals of enhancing health outcomes. CEO Thomas J. Appio expressed confidence in Jonathan's capacity to drive groundbreaking advancements.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Bausch Health Companies Inc.